Overall study schema for REAP-HD
| Study period | |||||
|---|---|---|---|---|---|
| Off-site randomi-sation | Post-allocation | ||||
| Enrolment Pre-randomisation | In person visit at time 0 | Follow-up phone call at 1 month | Close-out 4 months | ||
| Enrolment | |||||
| Recruitment of people with Huntington disease/family | X | ||||
| Informed consent from people with Huntington disease/family | X | ||||
| Informed consent from health professional at residential care facility | X | ||||
| Allocation | X | ||||
| Interventions | |||||
| REAP-HD | ♦———————————♦ | ||||
| Standard staff education | ♦———————————♦ | ||||
| Assessments | |||||
| Collection of demographic data, antipsychotic dosage 4 months prior to enrolment | X | ||||
| Blinded collection of current antipsychotic dosage | X | X | X | ||
| Blinded telephone collection of current NPI-Q score | X | X | |||
NPI-Q, Neuropsychiatric Inventory-Q; REAP-HD, REducing Anti-Psychotic use in residential care-Huntington Disease.